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Liposomes were first described by Bangham in 1965 while 
studying cell membranes. He found that liposomes are vesicular 
structures consisting of hydrated bilalyers which form spontaneously 
when phospholipids are dispersed in water. Since this, further studies 
into liposomes and their application in various fields such as medicine 
and research have been explored [1]. Liposomes are defined as 
structure consisting of one or more concentric pheres of lipid bilayers 
separated by water or aqueous buffer compartments. Phospholipids are 
the main component of naturally occurring bilayers. These 
phospholipids include phosphatidylcholines (PC), 
phosphatidylethanolamines (PE) and phosphatidylserines (PS).[2] The 
key common feature that bilayer-forming compounds share is their 
amphiphilicity i.e., they have defined polar and non polar regions. This 
is the reason the non-polar regions orientate themselves towards the 
interior away from the aqueous phase, the polar regions being in 
contact with it. Liposomes were discovered about 40 years ago by A.D. 
Bangham which has become the versatile tool in biology, biochemistry 
and medicine today. In 1960s, liposome has been used as a carrier to 
transport a wide variety of compounds in its aqueous compartment. 
Liposome can be formulated and processed to differ in size, 
composition, charge and lamellarity. To date liposomal formulations of 
anti-tumor drugs and antifungal agents have been commercialized. [3] 
The clinical potential of liposomes as a vehicle for replacement therapy 
in genetic deficiencies of lysosomal enzymes was first established in 
1970s.[4,5] Considerable progress was made during 1970s and 1980s 
in the field of liposome stability leading to long circulation times of 
liposomes after intravenous administration resulting in the 
improvement in bio-distribution of liposome. The important anti-
tumour drug doxorubicin had been formulated as liposome in 1980s to 
improve the therapeutic index. There are several mechanisms by which 
liposomes act within and outside the body which are as follows [6] 
1) Liposome attaches to cellular membrane and appears to fuse with 
them, releasing their content into the cell. 
2) Sometimes they are taken up by the cell and their phospholipids are 
incorporated into the cell membrane by which the drug trapped 
inside is released. 
3) In the case of phagocyte cell, the liposomes are taken up, the 
phospholipid walls are acted upon by organelles called lysosomes 
and the active pharmaceutical ingredients are released. 
1.1 Attractive biological properties of liposomes: 
 Liposomes are biocompatible. 
 Liposomes can entrap water-soluble (hydrophilic) pharmaceutical 
agents in their internal water compartment and water-insoluble 
(hydrophobic) pharmaceuticals into the membrane. 
 Liposome-incorporated pharmaceuticals are protected from the 
inactivating effect of external conditions; yet do not cause 
undesirable side reactions. 
 Liposomes provide a unique opportunity to deliver pharmaceuticals 
into cells or even inside individual cellular compartments. 
 Size, charge and surface properties of liposomes can be easily 
changed simply by adding new ingredients to the lipid mixture before 
liposome preparation and/or by variation of preparation methods 
1.2 Advantages of Liposomes: 
1) Provide controlled drug delivery 
2) Biodegradable, biocompatible, flexible 
3) Non ionic 
4) Can carry both water and lipid soluble drugs 
5) Drugs can be stabilized from oxidation 
6) Improve protein stabilization 
7) Controlled hydration 
8) Provide sustained release 
9) Targeted drug delivery or site specific drug delivery 
10) Stabilization of entrapped drug from hostile environment 
11) Alter pharmacokinetics and pharmacodynamics of drugs 
12) Can be administered through various routes 
13) Can incorporate micro and macro molecules 
14) Act as reservoir of drugs 
15) Therapeutic index of drugs is increased 
16) Site avoidance therapy 
17) Can modulate the distribution of drug 
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Fig.1; Structure of Liposome (Source: google.com) 
 
2. Classification of Liposomes 
2.1 Based on composition and mode of drug delivery 
2.1.1. Conventional liposomes:  
Composed of neutral or negatively charged phospholipids 
and cholesterol. Subject to coated pit endocytosis, contents ultimately 
delivered to Lysosomes if they do not fuse with the endosomes, useful 
for E.E.S targeting; rapid and saturable uptake by R.E.S; short circulation 
half life, dose dependent pharmacokinetics. 
2.1.2. pH sensitive liposomes :  
Composed of phospholipids such as phosphatidyl 
ethanolamine, dioleoyl phosphatidyl ethanolamine. Subjected to coated 
pit endocytosis at low pH, fuse with cell or endosomes membrane and 
release their contents in cytoplasm; suitable for intra cellular delivery of 
weak base and macromolecules. Biodistribution and pharmacokinetics 
similar to conventional liposomes. 
2.1.3. Cationic Liposomes:  
Composed of cationic lipids. Fuse with cell or endosome 
membranes; suitable for delivery of negatively charged macromolecules 
(DNA, RNA); ease of formation, structurally unstable; toxic at high dose, 
mainly restricted to local administration 
2.1.4. Long circulating or stealth liposomes: 
Composed of neutral high transition temperature lipid, 
cholesterol and 5-10% of PEG-DSPE. Hydrophilic surface coating, low 
opsonisation and thus low rate of uptake by RES long circulating half 
life (40 hrs); Dose independent Pharmacokinetics 
2.1.5. Immuno liposomes:  
Conventional or stealth liposomes with attached Antibody or 
Recognition Sequence. Subject to receptor mediated endocytosis, cell 
specific binding (targeting); can release contents extracellularly near 
the target tissue and drugs diffuse through plasma membrane to 
produce their effects. 
2.1.6. Magnetic Liposomes:  
Composed of P.C, cholesterol and small amount of a linear 
chain aldehyde and colloidal particles of magnetic Iron oxide. These are 
liposomes that indigenously contain binding sites for attaching other 
molecules likeantibodies on their exterior surface. Can be made use by 
an external vibrating magnetic field on their deliberate, on site, rapture 
and immediate release of their components. 
2.1.7. Temperature (or) heat sensitive liposomes:  
Composed of Dipalmitoyl P.C. These are vesicles showed 
maximumrelease at 41o, the phase transition temperature of 
Dipalmitoyl P.C. Liposomesrelease the entrapped content at the 
targetcell surface upon a brief heating to thephase transition 
temperature of theliposome membrane. 
2.2Based on Size and Number of Lamellae 
2.2.1. Multi lamellar vesicles (M.L.V):  
(Size 0.1 - 0.3 micro meter) Have more than one bilayer; 
moderate aqueous volume to lipid ratio 4: 1 mole lipid. Greater 
encapsulation of lipophilic drug, mechanically stable upon long term 
storage, rapidly cleared by R.E.S, useful for targeting the cells of R.E.S, 
simplest to prepare by thin film hydration of lipids in presence of an 
organic solvent. 
a) Oligo lamellar vesicles or Paucilamellar vesicles – Intermediate 
between L.U.V & MLV. 
b) Multi vesicular liposomes – Separate compartments are present in a 
single M.L.V. 
c) Stable Pluri lamellar vesicles – Have unique physical and biological 
properties due to osmotic compression. 
2.2.2. Large Unilamellar Vesicles (L.U.V):  
(Size 0.1 - 10 micro meter)Have single bilayer, high aqueous 
volume tolipid ratio (7: 1 mole lipid), useful forhydrophilic drugs, high 
capture of macromolecules; rapidly cleared by R.E.S.Prepared by 
detergent dialysis, etherinjection, reverse phase evaporation oractive 
loading methods. 
2.2.3. Small Unilamellar Vesicles (S.U.V): 
(Size 0.1 micro meters) Single bilayer, homogeneous in size, 
thermodynamically unstable, susceptible to aggregation and fusion at 
low or no charge, limited capture of macro molecules, low aqueous 
volume to lipid ratio (0.2 : 1.5 : 1 mole lipid) prepared by reducing the 
size of M.L.V or L.U.V using probe sonicator or gas extruder or by active 
loading or solvent injection technique. 
 
3. Preparation Method Ofliposome[7-44] 
A) Multilamellar Liposomes (MLV) 
(i) Lipid Hydration Method 
a) This is the most widely used method for the preparation of MLV. 
The method involves drying a solution of lipids so that a thin film 
is formed at the bottom of round bottom flask and then hydrating 
the film by adding aqueous buffer and vortexing the dispersion for 
some time. The hydration step is done at a temperature above the 
gel-liquid crystalline transition temperature Tc of the lipid or 
above the Tc of the highest melting component in the lipid 
mixture. The compounds to be encapsulated are added either to 
aqueous buffer or to organic solvent containing lipids depending 
upon their solubilities. MLV are simple to prepare by this method 
and a variety of substances can be encapsulated in these 
liposomes. The drawbacks of the method are low internal volume, 
low encapsulation efficiency and the size distribution is 
heterogeneous. 
b) MLVs with high encapsulation efficiency can be prepared by 
hydrating the lipids in the presence of an immiscible organic 
solvent (petroleum ether, diethyl ether). The contents are 
emulsified by vigorous vortexing or sonication. The organic 
solvent is removed by passing a stream of nitrogen gas over the 
mixture. MLVs are formed immediately in the aqueous phase after 
the removal of organic solvent. The main drawback of this method 
is the exposure of the materials to be encapsulated to organic 
solvent and to sonication. 
(ii) Solvent Spherule Method 
A method for the preparation of MLVs of homogeneous size 
distribution was proposed by Kim et al. The process involved dispersing 
in aqueous solution the small spherules of volatile hydrophobic solvent 
in which lipids had been dissolved. MLVs were formed when controlled 
evaporation of organic solvent occurred in a water bath. 
B) Small Unilamellar Liposomes (SUV) 
(i) Sanitation Method 
Here MLVs are sonicated either with a bath type sonicator or 
a probe sonicator under an inert atmosphere. The main drawbacks of 
this method are very low internal volume/encapsulation efficiency, 
possibly degradation of phospholipids and compounds to be 
encapsulated, exclusion of large molecules, metal contamination from 
probe tip and presence of MLV along with SUV. Recently, Oezden and 
Hasirci prepared polymer-coated liposomes by this method. 
(ii) French Pressure Cell Method 
The method involves the extrusion of MLV at 20,000 psi at 
4°C through a small orifice. The method has several advantages over 
sonication method. The method is simple rapid, reproducible and 
involves gentle handling of unstable materials (Hamilton and Guo, 
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1984). The resulting liposomes are somewhat larger than sonicated 
SUVs. The drawbacks of the method are that the temperature is difficult 
to achieve and the working volumes are relatively small (about 50 ml 
maximum). 
(iii) A new method for the preparation of SUV was given by Lasic et al. 
They deposited egg phosphatidylcholinc mixed with 1.5 %w/v of 
cetyltetramethylammonium bromide (a detergent) in CHCI3/CH3OH on 
various supports for example silica gel powder, zeolite X, zeolite ZSM5. 
After the removal of organic phase, the system was resuspended by 
shaking or stirring in distilled water or 5 mMNaCl. There was some loss 
of phospholipid (about 10-20%) due to adsorption on the supports. The 
loss was 70% and 95% in the case of silica gel and zeolite ZSMS 
respectively. A homogenous population of vesicle with average 
diameter of 21.5 nm was obtained when zeolite X (particle size of 0.4 
mm) was used as a support. 
C) Large Unilamellar Liposomes (LUV) 
They have high internal volume/encapsulation efficiency and 
are now days being used for the encapsulation of drugs and 
macromolecules. 
(i) Solvent Injection Methods 
(a) Ether Infusion Method 
A solution of lipids dissolved in diethyl ether or 
ether/methanol mixture is slowly injected to an aqueous solution of the 
material to be encapsulated at 55-65°C or under reduced pressure. The 
subsequent removal of ether under vacuum leads to the formation of 
liposomes. The main drawbacks of the method are that the population is 
heterogeneous (70-190 nm) and the exposure of compounds to be 
encapsulated to organic solvents or high temperature. 
(b) Ethanol Injection Method 
A lipid solution of ethanol is rapidly injected to a vast excess 
of buffer. The MLVs are immediately formed. The drawbacks of the 
method are that the population is heterogeneous (30-110 nm), 
liposomes are very dilute, it is difficult to remove all ethanol because it 
forms azeotrope with water and the possibility of various biologically 
active macromolecules to inactivation in the presence of even low 
amounts of ethanol. 
(ii) Detergent Removal Methods 
The detergents at their critical micelles concentrations have 
been used to solubilize lipids. As the detergent is removed the micelles 
become progressively richer in phospholipid and finally combine to 
form LUVs. The detergents were removed by dialysis. The advantages of 
detergent dialysis method are excellent reproducibility and production 
of liposome populations, which are homogenous in size. The main 
drawback of the method is the retention of traces of detergent(s) within 
the liposomes. A commercial device called LIPOPREP (Diachema AG, 
Switzerland), which is a version of dialysis system, is available for the 
removal of detergents. Other techniques have been used for the removal 
of detergents: (a) by using Gel Chromatography involving a column of 
Sephadex G-25,  
(b) By adsorption or binding of Triton X-100 (a detergent) to Bio-Beads 
SM-2. 
(c) By binding of octylglucoside (a detergent) to Amberlite XAD-2 beads. 
(iii) Reserves Phase Evaporation Method 
 First water in oil emulsion is formed by brief sonication of a 
two-phase system containing phospholipids in organic solvent and 
aqueous buffer. The organic solvents are removed under reduced 
pressure, resulting in the formation of a viscous gel. The liposomes are 
formed when residual solvent is removed by continued rotary 
evaporation under reduced pressure. With this method high 
encapsulation efficiency up to 65% can be obtained in a medium of low 
ionic strength for example 0.01 M NaCl. The method has been used to 
encapsulate small, large and macromolecules. The main disadvantage of 
the method is the exposure of the materials to be encapsulated to 
organic solvents and to brief periods of sonication. These conditions 
may possibly result in the denaturation of some proteins or breakage of 
DNA strands. We get a heterogeneous sized dispersion of vesicles by 
this method. Modified Reverse Phase Evaporation Method was 
presented by Handa et al. and the main advantage of the method is that 
the liposomes had high encapsulation efficiency (about 80%). The 
Reverse Phase Evaporation Method of Szoka and Papahadjopoulos have 
also been modified to entrap plasmids without damaging DNA strands. 
(iv) Calcium-Induced Fusion Method 
This method is used to prepare LUV from acidic 
phospholipids. The procedure is based on the observation that calcium 
addition to SUV induces fusion and results in the formation of 
multilamellar structures in spiral configuration (Cochleate cylinders). 
The addition of EDTA to these preparations results in the formation of 
LUVs. The main advantage of this method is that macromolecules can he 
encapsulated under gentle conditions. The resulting liposomes are 
largely unilamellar, although of a heterogeneous size range. The chief 
disadvantage of this method is that LUVs can only be obtained from 
acidic phospholipids.  
(v) Microfluldization Method 
Mayhew et al. suggested a technique of 
microfluidization/microemulsification/ homogenization for the large-
scale manufacture of liposomes. The reduction in the size range can be 
achieved by recycling of the sample. The process is reproducible and 
yields liposomes with good aqueous phase encapsulation. Riaz and 
Weiner prepared liposomes consisting of egg yolk, cholesterol and brain 
phosphatidylserindia sodium salt (57:33:10) by this method. First MLV 
were prepared by these were passed through a Microluidizer 
(Microlluidics Corporation, Newton, MA, USA) at 40 psi inlet air 
pressure. The size range was 150-160 nm after 25 recylces. In the 
Microluidizer, the interaction of fluid streams takes place at high 
velocities (pressures) in a precisely defined micro channel, which are 
present in an interaction chamber. In the chamber pressure reaches up 
to 10,000 psi this can be cause partial degradation of lipids. 
(vi) Extrusion under nitrogen through polycarboriate filters LUV can be 
prepared by passing MLV under nitrogen through polycarbonate 
membrane filters. The vesicles produced by this method have narrow 
size distribution. The extrusion is done under moderate pressures (100-
250 psi). A special filter holder is required. Such devices are available 
commercially under the trade names such as LUVET and EXTRUDER 
and are equipped with a recirculation mechanism that permits multiple 
extrusions with little difficulty. Small quantities of liposome 
preparations (about 10 ml) can be easily prepared by the help of a 
commercial extruder. Riaz and Weiner prepared liposomes by this 
technique. The liposomes contained phosphatidylcholine from egg yolk 
and crude phosphoinositide sodium salt in the ratio of 4:1 and the lipid 
concentration was 12.5 /mole/ml. MLVs were passed through Extruder 
Lipex Membrane Inc., Vancouver, Canada) ten times through a stalk of 
two 100 nm polycarbonate filters (Nudeopore Pleasanton, CA, USA) 
employing nitrogen pressures upto 250 psi. Freeze fracture electron 
microscopy and p31-FT NMR revealed that the liposomes were 
unilamellar. Photon Correlation Spectroscopy revealed that the size 
range was 99-135 nm. 
(vii) Lasic et al. reported a method for the instant formation of a rather 
homogeneous preparation of LUV by a simple technique. The formation 
of multilammelar liposomes is prevented by inducing a surface charge 
(+ve) on the bilayer while the size of the vesicles is controlled by the 
topography of the wafer support surface on which phospholipid film 
was formed. They deposited 0.5-1.0 mg egg yolk lecithin doped with 3 
ml of CHCl3/CH3OH on a specially etched 2-inch silicon wafer. This 
wafer was put in place of the original bottom of an Erlenmeyer flask 
that is bottom of the flask is replaced by wafer. After having dried 
overnight at 102 tore (about 1 Pa), the film was resuspended by gentle 
shaking in 1-2 ml water. Liposomes were formed instantly. The 
contamination of liposomes with large structures such as MLVs, giant 
vesicles and phospholipids particles was ruled out by video enhanced 
phase contrast microscopy. 
(viii) A method for the extemporaneous preparation of LUVs has been 
described by Liautard and Phillippot. The method was recommended 
for immediate clinical use of liposomes. 
(ix) Freeze-Thaw Method 
SUVs are rapidly frozen and followed by slow thawing. The 
brief sonication disperses aggregated materials to LUV. The formation 
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of unilamellar vesicles is due to the fusion of SUV during the processes 
of freezing and or thawing. This type of fusion is strongly inhibited by 
increasing the ionic strength of the medium and by increasing the 
phospholipid concentration. The encapsulation efficiencies from 20 to 
30% were obtained. 
(D) Giant Liposomes 
(i) The procedure for the formation of giant liposomes involves the 
dialysis, of a methanol solution of phosphatidylcholine in the presence 
of methyl glucoside detergent against an aqueous solution containing 
up to 1 M NaCl. The liposomes range in diameter from 10 to 100 mm. 
(ii) A method for the formation of giant single lamellar liposomes with 
size in the range of 10 to 20 prn by the removal of sodium 
trichloroacetate by dialysis was presented by Oku and MacDonald. 
(E) Multivesicular Liposomes 
(i) The formation of multivesicular liposomes has been reported by Kim 
et al.. The water in oil emulsion was converted to organic solvent 
spherules by the addition of the emulsion to across solution. The 
evaporation of organic solvent resulted in the formation of 
multivesicular vesicles. The diameter of liposomes ranges from 5.6 to 
29 pm. The materials which can be encapsulated include glucose, EDTA, 
human DNA. These liposomes have very high encapsulation efficiency 
(up to 89%). 
(ii) Cullis et al. (1987) found that when MLV preparations were 
subjected to five cycles of freeze on liquid nitrogen)-thaw and followed 
by thawing in warm water, the liposomes of high encapsulation 
efficiency (up to 88%) could be obtained. Freeze fracture electron 
micrographs revealed vesicles within vesicles. 
(F) Assymetric Liposomes 
It has been shown that the phospholipid distribution in 
natural membranes is asymmetric. For example phosphatidytcholine 
and sphingomyelin concentrate at the outer half of lipid bilayer whereas 
phosphatidyl ethanolamine, phosphatidyl inositoland 
phosphatidylserine are mainly localized in the inner half of bilayer. Due 
to this, attempts have been made to prepare LUVs in which 
phospholipid distribution in both halves of bilayer is different. It 
appears that as model membranes the asymmetric liposomes are 
nearer to natural membranes than the conventional unilamellar 
liposomes. In the latter the phospholipids distribution is symmetrical in 
bilayer. 
(i) Cestaro et al. (1982) described a procedure for the preparation of 
asymmetric liposomes which contain cerebroside sulfate only at the 
outer leaflet of phospholipids bilayer. Cerebroside sulfate was adsorbed 
on to a filter paper (cellulose) support and then the support was 
incubated with small or large fused unilamellar liposomes. After six 
hours sulfatide contents reached about 6 mole percentage of the total 
quantity of phospholipid, corresponding to about 10 mole % of 
phospholipid present in the outer layer. The sulfatide could not be 
removed by washing with 1M NaCl or 1M urea. 
(ii) Pagano et al. (1981) reported the formation of asymmetric 
phospholipid vesicles, which contained fluorescent lipid analogue in 
either the outer or inner leaflet of the liposome bilayer. The procedure 
is based on the observation that the lipid analogues undergo rapid 
exchange (transfer) between the vesicles populations. 
(iii)Denkins and Schroit (1986) prepared asymmetric liposomes by 
the enzymatic conversion of the fluorescent lipid-analogue of 
phosphatidylserine (NBD-PS) in the outer leaflet of LUV to NBD- 
phosphatidylethanolamine (NBD-PE). 
(iv) Low and Zilversmit (1980) reported that lipid exchange proteins 
could be effectively being used so remove phosphatidylinositol at the 
outer leaflet of unilamellar liposomes. Therefore, it appears that these 
proteins may be used for the preparation of asymmetric liposomes. 
(v) Collis et al. (1987) found that in SUV, distribution of lipid was not 
symmetrical and ratio of lipid in the outer monolayer to lipid in the 
inner monolayer could be as large as 2:1. Therefore, small unilamellar 
liposomes can be also be called as asymmetric to some extent. 
 
4. Characterization 
4.1. Particle Size and Surface Charge 
The droplet size and zeta potential of the liposomes was 
determined by a Laser Scattering Particle Size Distribution Analyzer 
and Zeta Potential Analyzer at room temperature. One ml of the 
liposome suspensions was diluted with 14 ml and 2 ml deionized water, 
respectively. 
4.2. Transmission Electron Microscopy 
Transmission Electron Microscopy (TEM) was used to 
visualize the liposomal vesicles. The vesicles were dried on a copper 
grid and adsorbed with filter paper. After drying, the sample was 
viewed under the microscope at 10–100 k magnification at an 
accelerating voltage of 100 kV. 
4.3. Entrapment Efficiency (%EE) and Loading Efficiency 
The concentration of MX in the formulation was determined 
by HPLC analysis after disruption of the vesicles (liposomes) with 
Triton X-100 (0.1% w/v) at a 1:1 volume ratio and appropriate dilution 
with PBS (pH 7.4). The vesicle/Triton X-100 solutions was centrifuged 
at 10,000 rpm at C for 10 min. The supernatant was filtered with a 0.45 
m nylon syringe filter. The entrapment efficiencies and the loading 
efficiencies of the MX-loaded formulation were calculated by (1) and 
(2), respectively. (1) Where is the concentration of MX loaded in the 
formulation as described in the above methods, and is the initial 
concentration of MX added into the formulation (2) where is the total 
amount of MX in the formulation and is the total amount of PC added 
into the formulation. 
4.4. Stability Evaluation of Liposomes 
Liposomes were stored at C and C (room temperature, RT) 
for 30 days. Both the physical and the chemical stability of MX were 
evaluated. The physical stability was assessed by visual observation for 
sedimentation and particle size determination. The chemical stability 
was determined by measuring the MX content by HPLC on days 0, 1, 7, 
14, and 30. 
 
5. Advancements in Liposomes  
There are various types of liposomes classified on the basis of 
the targeted site, technology used, and use. The drug release from the 
liposomal action occurs by different mechanisms and the targeting of 
the liposomes to a specific site is achieved in various ways. All the types, 
mechanisms of action and targeting strategies of the liposomes have 
been reviewed [45].  To overcome the drawbacks of the liposomes and 
to further enhance the drug delivery some advancement were made to 
conventional liposomes. This brought up the development of newer 
concepts like Plarosomes, featuring the approaches to target the 
Anthracycline drugs at the site of action, Pulsatory liposomes for the 
well-controlled delivery of biotechnological products, Thermosensitive 
liposomes in combination with localized hyperthermia, to improve the 
targeted drug delivery for more effective management of melanoma, 
Gaint liposomes for stability and the simulation of the cells models, Dry 
liposomes using sugars which stabilize the membranes by lowering lipid 
phase transition temperature and prevent liposome aggretation and 
fusion, thus achieving a stable liposomal formulation. This stabilization 
mechanism was explained that the sugar molecules form hydrogen 
bonds with the polar heads of the phospholipids on the liposomal 
membranes, Sterically stabilized liposomes, challenging the stability 
problem. Detailed information on the preparation and evaluation of 
every type of liposomes stated above can be studied from the citations 
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Table 1: Application of Liposomes 
Drug Method of Preparation Composition Achievement Ref 
Ketaconazole Thin film hydration Soya lecithin, cholesterol tocopheryl acetate Improve therapeutic 
response and reduce 
adverse effects 
[50] 
Acetazolamide Reverse phase evaporation 
and 
thin film hydration 
Egg phosphotidyl choline, cholesterol (steryl 
amine and diacetyl phosphate as + or – charge 
inducers) 
Increasing the stability and 




amphotericin B methyl 
ester (MFAME) 
chloroform film method dimyristoyl phosphatidylcholine 
cholesterol or ergosterol  
Reduction In toxicity of 
amphotericin 
[52] 
Cyproterone acetate solvent evaporation  




better penetration [53] 
Doxorubicin Thin Film hydration 
method 
Cholesterol  
Phosphatidylserhe, phosphatidylglycerol or 
cardiolipin 
Saturated or unsaturated Phospholipid acyl 
chains 
Reduction I cardiotoxicity 
and enhanced antitumor 
activity 
[54] 
Ferrous sulphate thin-film hydration, thin-
film sonication, reverse-
phase evaporation and 
freeze-thawing,  
egg lecithin, 10% (mol/mol)  
cholesterol and 10% (mol/mol) Tween 80. 
Ascorbic acid 
Increased electrostatic and 
steric stability 
[55] 
Hydroxyzine Ethanol injection method 
and lipid film hydration 
method 
L-α-phosphatidylcholine 95%(PC), cholesterol Increase in drug 
concentration in skin and 
enhanced efficacy 
[56] 
TopotecanHCl chloroform film method soyabean phosphatidylcholine  
or hydrogenated soybean phosphatidylcholine 
and cholesterol (PEG Ligated) 
Improved stability and 
enhanced efficacy by 
accumulation in tumor cells 
[57] 
Paclitaxel thin-film hydration 
method 










Table 2: List of Marketed Liposomal Products [59] 
S.No Product name Drug Manufacturer  
1 Abelcet Amphotericin B The liposome company [USA] 
2 Allovecti-711 HLB-B7 plasmid Vical incorporation[USA] 
3 3 AmBisome Amphotericin B NeXatar pharmaceuticals[USA] 
4 Amphocil Amphotericin B SEQUUS Pharmaceuticals[USA] 
5 Doxilt Doxorubicin SEQUUS Pharmaceuticals[USA] 




In the development of novel drug delivery system (NDDS), 
Liposomes are highly useful for cancer therapy and vaccination. DOXIL, 
SPI077, Lipoplatin, S-CKD-602 have been approved or in advance trial 
of PEGylated liposomal formulations. PEG-derivatized liposomes with 
increased stability can easily be modified using a wide array of targeting 
moieties (MAb, ligands) to deliver the drug specifically to the target 
tissues with increasing accuracy. The development of liposome delivery 
to particular subcellular compartments is a field of great interest in 
different fields, such as gene therapy and vaccination. The interaction of 
stealth liposomes with cell membranes, and release of the drug in the 
neighborhood of target tissues are still under investigation, but some 
recent studies indicate that the use of detachable PEG may facilitate cell 
penetration and/or intracellular delivery of vesicles. PEG-coated 
liposomes are becoming increasingly important, giving technological 
and biological stability to liposomal systems. Application of Liposomes 
is also reviewed in this article. 
 
Acknowledgement 
We would like to express our heartfelt thanks to our beloved 
parents for their blessings, our teacher’s and friends and Miss. Priti 





[1] Bangham, A.D. Liposomes in Biological Systems, John Wiley and 
Sons: Chichester, 1980. 
[2] Chapman D. Liposomal technology. 1983; 1:1-18. 
[3] Jayakrishnan, A.; Latha, M.S. Controlled and Novel Drug Delivery, 
B.S. Pub: New Delhi, 1997. 
[4] Sessa, G.; Weismann, G. Journal of Journal of Biological Chemistry, 
1970;, 245: 3295. 
[5] Gregoriadis, G. Methods in Enzymology, 1976; 44: 278. 
[6] Dunnick, J. K.; Rooke, J D.; Aragon, S.; Kriss, J. P. Cancer. Res., 1976; 
36: 2385-2389. 
[7] Bangham A.D., Standish M.M. and Watlins J.C. J. Mol. Biol. 1965; 13: 
238. 
[8] Bangham A.D., Hill M.W. and Miller N.G.A. n: Methods in Membrane 
Biology (Korn N.D., ed.) Plenum. N.Y., 1974; Vol.1, p.l.  
[9] Papahadjopoulos D. and Watkins J.C. Biochimicaet Biophysica, 
1978; 135: 639. 
[10] Gruner S.M., Leak R.P., Jan off S. and Ostro M.J. Biochem. 1985; 24: 
2833. 
[11] Kim S., Jacobs R.E. and White S.H. Biochimicaet Biophysica Acta, 
1985; 812: 793. 
[12] Oezden M.Y. and Hasirci V.N. Biochimicaet Biophysica Acta. 1991; 
1075: 102. 
[13] Hamilton R.L. and Guo L.S.S. In: Liposome Technology (Gregoriadis 
G. ed.) CRC Press, Florida, 1984; Vol.1, Chapter 4, p.37. 
Navneet Kumar Verma and Asha Roshan/ Liposomes: A Targeted Drug Delivery System- A Review 
 
© ASD Publisher All rights reserved.                                                                                                                                                                                                                 70 
[14] Lasic D.D., Kidric J. and Zagorc S. Biochimicaet Biophysica Acta. 
1987; 896: 117. 
[15] Deamer D. and Bangham A.D. Biochimicaet Biophysica Acta. 1976; 
443: 629. 
[16] Schieren H., Rudolph S., Findelstein M., Coleman P. and Weissmann 
G.  Biochimicaet Biophysica Acta. 1978; 542: 137. 
[17] Batzri S. and Korn E.D.  Biochimicaet Biophysica. 1973; 298: 1015. 
[18] Kagawa Y. and Racker E. Journal of Biological Chemistry. 1974; 246: 
5477. 
[19] Milsmann M.H.W., Schwendener R.A. and Wader H.  Biochimicaet 
Biophysica Acta. 1978; 512: 147. 
[20] Alpes H., Allmann K., Plattner H., Reichert J., Rick R. and Schulz S. 
Biochimicaet Biophysica Acta. 1986; 862: 294. 
[21] Enoch H.G. and Strittmatter P. Proceedings of the National 
Academy of Sciences, USA. 1979;76: 145. 
[22] Gerritson W.J., Verkley A.J., Zwaal R.F.A. and van Deenan L.L.M.  
European Journal of Biochemistry, 1978; 85: 255. 
[23] Philippot J.R., Mutafschicv S. and Liautard J.P. Biochimicaet 
Biophysica Acta. 1985; 821: 79. 
[24] Szoka F. Jr. and Papahadjopoulos D.  Proceedings of the National 
Academy of Sciences, USA. 1978; 75: 4194. 
[25] Handa T., Takeuchi H., Phokubo Y. and Kawashima Y.  Chemical& 
pharmaceutical bulletin. 1987; 35: 748. 
[26] Haga N. and Yogi K.  Journal of Clinical Biochemistry and Nutrition. 
1989; 7: 175. 
[27] Papahadjopoulos D. and Vail W.J. Annals of the New York Academy 
of Sciences. 1978; 308: 259. 
[28] Mayhew E., Lazo R., Vail WJ, King J. and Green A.M.  Biochimicaet 
Biophysica Acta. 1984; 775: 169. 
[29] Riaz M. and Weiner N.  Pakistan Journal of Pharmaceutical Sciences. 
1995; 
[30] Jousma H., Talsma H., Spies F., Joosten J.G.H., Junginger H.E. and 
Crommelin D.J.A.  International Journal of Pharmaceutics. 1987; 35: 
263. 
[31] Riaz M. and Weiner N.  Pakistan Journal of Pharmaceutical Sciences. 
1994; 7: 61. 
[32] Lasic D.D., Belie A. and Valentincic T. J. Ant. Client. Soc. 1988; 110: 
970. 
[33] Liautard J.P. and Phillippot J.R. Journal of Liposome Research. 1993; 
63. 
[34] Pick U. Arch. Biochem. Biophys. 1981; 212: 186. 
[35] Ohsawa T., Miura H. and Harada K.  Chemical& pharmaceutical 
bulletin. 1985; 33: 3945. 
[36] Liu L. and Yonetaini T. Journal of Microencapsulation. 1994; 11: 
409. 
[37] Oku N., Scheerer J.F. and McDonald R.C. Biochimicaet Biophysic 
acta. 1982; 692: 384. 
[38] Oku N. and MacDonald R.C. Biochimicaet Biophysica Acta. 1983; 
734: 54. 
[39] Kim S., Turker M.S., Chi E.Y., Scla S. and Martin G.M.  Biochimicaet 
Biophysica Acta. 1983; 728: 339. 
[40] Cullis R.P., Hope M.J., Bally M.B., Madden T.D. and Jan off AS.  In: 
Liposomes from Biophysics to Therapeutics (Ostro M. J., Ed.) 
Marcel Dekker, N.Y., Chapter 2, 1987; p.39.39 
[41] Op den Kamp J.A.F.  Ann. Rev. Biochem. 1979; 48: 47. 
[42] Cestaro B., Pistolesi E., Hershkowitz N. and Galt S.  Biochimicaet 
Biophysica Acta. 1982; 685:13. 
[43] Pagano R.E., Martin O.C., Schroit A.J. and Struck D.K.  Biochemistry. 
1981; 20: 4920. 
[44] Low M.G. and Zilversmit D.D.  Biochimicaet Biophysica Acta. 1980; 
596: 223. 
[45] Christopher Kirby, Jacqui Clarke, Gregory Gregoriadis. Effect of the 
Cholesterol Content of Small Unilamellar. Liposomes on their 
Stability in vivo and in vitro. Biochem. J., 1980; 186: 591-598.  
[46] Omar Moh’d Atrouse. The Effect of liposome Composition and 
Temperature on the Stability of Liposomes and the Interaction of 
liposomes with Human Neutrophils. Pakisthan Journal of Biological 
Sciences, 2002; 5(9): 948-951.  
[47] Arkadiusz Kozubek, Jerzy Gubernator, Ewa Przeworska, Maria 
Stasiuk Liposomal drug delivery, a novel approach: PLA Rosomes. 
Acta Biochimica Polonica, 2000; 47(3): 639–649.  
[48] Popescu D, Popescu AG, Amuzescu B Pulsatory. Liposomes – A 
Possible Biotechnological Device for Controlled Drug Delivery. I. 
The Liposome Swelling. Romanian J. Biophys., 2010; 20(1): 37–46.  
[49] Tiwari Sandip B, Udupa N, Rao BSS, Uma Devi P. Thermosensitive 
Liposomes And Localised Hyperthermia – An Effective Bimodality 
Approach For Tumour Management. Indian Journal of 
Pharmacology, 2000; 32: 214-220.  
[50] Rakesh P Patel, Hardik Patel, Ashok H Baria. Formulation and 
Evaluation of Liposomes of Ketoconazole. International Journal of 
Drug Delivery Technology, 2009; 1(1): 16-23.  
[51] Rania M Hathout, Samar Mansour, Nahed D Mortada, Ahmed S 
Guinedi. Liposomes as an Ocular Delivery System for 
Acetazolamide. In Vitro and In Vivo Studies. AAPS Pharm SciTech., 
2007; 8(1): E1-12.  
[52] Barbara Cybulska, Karolina Kupczyk, Joanna Szlinder-Richert, 
Edward Borowski. Comparative in vitro studies on liposomal 
formulations of amphotericin B and its derivative, N-methyl-N-D-
fructosyl amphotericin B methyl ester (MFAME). Acta Biochimica 
Polonica, 2002; 49(1): 67-75.  
[53] Soleiman Mohammadi-Samani, Hashem Montaseri, Minoo 
Jamshidnejad. Preparation and Evaluation of Cyproterone Acetate 
Liposome for Topical Drug Delivery. Iranian Journal of 
Pharmaceutical Sciences Autumn, 2009; 5(4): 199-204.  
[54] Paul G Tardi, Nancy L Boman, Pieter R Cullis. Liposomal 
Doxorubicin. J. drug targeting., 1996; 4(3): 129-140.  
[55] Shuqin Xia, Shiying Xu. Ferrous sulfate liposomes: preparation, 
stability and application in fluid milk. Food Research International, 
2005; 38: 289–296.  
[56] Abeer AW Elzainy et al; Hydroxyzine from Topical Phospholipid 
Liposomal Formulations: Evaluation of Peripheral Antihistaminic 
Activity and Systemic Absorption in a Rabbit Model. AAPS Pharm 
Sci., 2003; 5(4): 41-48.  
[57] Yan-Li Hao et al; In Vitro and In Vivo Studies of Different 
Liposomes Containing Topotecan. Arch Pharm Res., 2005; 28(5): 
626-635.  
[58] Tao Yang et al; Enhanced solubility and stability of PEGylated 
liposomal paclitaxel: In vitro and in vivo evaluation. International 
Journal of Pharmaceutics, 2007; 338: 317–326.  
[59] Parveen Goyal et al; Liposomal drug delivery systems Clinica 
Applications, Acta Pharm, 2005; 55(3): 1-25. 
 
 
 
